Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sequence of novel agents in multiple myeloma: an instrumental variable analysis.
Baz R, Miladinovic B, Patel A, Ho VQ, Shain KH, Alsina M, Nishihori T, Ochoa-Bayona JL, Sullivan DM, Dalton WS, Djulbegovic B. Baz R, et al. Among authors: djulbegovic b. Leuk Res. 2013 Sep;37(9):1077-82. doi: 10.1016/j.leukres.2013.06.005. Epub 2013 Jun 25. Leuk Res. 2013. PMID: 23809054
Rapid infusion rituximab for maintenance therapy: is it feasible?
Patel J, Ho M, Ho V, Bello C, Djulbegovic B, Sokol L, Wetzstein G. Patel J, et al. Among authors: djulbegovic b. Leuk Res Treatment. 2013;2013:629283. doi: 10.1155/2013/629283. Epub 2013 Oct 31. Leuk Res Treatment. 2013. PMID: 24288618 Free PMC article.
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Mhaskar R, et al. Among authors: djulbegovic b. Cochrane Database Syst Rev. 2017 Dec 18;12(12):CD003188. doi: 10.1002/14651858.CD003188.pub4. Cochrane Database Syst Rev. 2017. PMID: 29253322 Free PMC article. Review.
Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma.
Alsina M, Fonseca R, Wilson EF, Belle AN, Gerbino E, Price-Troska T, Overton RM, Ahmann G, Bruzek LM, Adjei AA, Kaufmann SH, Wright JJ, Sullivan D, Djulbegovic B, Cantor AB, Greipp PR, Dalton WS, Sebti SM. Alsina M, et al. Among authors: djulbegovic b. Blood. 2004 May 1;103(9):3271-7. doi: 10.1182/blood-2003-08-2764. Epub 2004 Jan 15. Blood. 2004. PMID: 14726402 Free article. Clinical Trial.
Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B. Mhaskar R, et al. Among authors: djulbegovic b. Cochrane Database Syst Rev. 2012 May 16;(5):CD003188. doi: 10.1002/14651858.CD003188.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2017 Dec 18;12:CD003188. doi: 10.1002/14651858.CD003188.pub4. PMID: 22592688 Updated. Review.
Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials.
Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A. Kharfan-Dabaja MA, et al. Among authors: djulbegovic b. J Hematol Oncol. 2013 Jan 4;6:2. doi: 10.1186/1756-8722-6-2. J Hematol Oncol. 2013. PMID: 23289975 Free PMC article. Review.
385 results